ClinPhone, a clinical trial technology suite, opened a Paris office with a gala party. Damien Tremolet, director of operations, will lead the new office, centrally located in the business center of the Gare de Lyon station. He’ll be supported by Jacques Rudelle, an associate director of business development. “Customer service is a vital part of any successful business and ClinPhone prides itself on providing the best possible support to all of its clients regardless of location,” said Steve Kent, CEO, ClinPhone.

The Swedish pharmaceutical company Biovitrum completed the review of its research and development organization as announced in November, 2007. Now Biovitrum will focus on specialist care pharmaceuticals, as well as taking its projects all the way to market. Consequently, Biovitrum is in the process of out-licensing a majority of the company’s primary care research. “The size, flexibility and competence of our new R&D organization make us well equipped to effectively deliver current and future specialist care products all the way to the market. The present staffing reduction and R&D restructuring is a necessary, albeit painful, step to ensure Biovitrum’s continued route to future growth,” said Martin Nicklasson, CEO of Biovitrum.

{embed=“includes/banner_ads” loc=“Middle”}

ADAM, a provider of health information, signed a licensing agreement with the Cleveland Clinic Health System. The Cleveland Clinic will integrate ADAM’s library of health articles, guides, health risk assessment tools, and imagery into its existing online health information portal at eight member hospitals. Patients seeking information on medical topics, conditions, or diagnoses can visit the websites for each hospital. “The Cleveland Clinic serves a large and diverse population, both internally and externally, through our network of hospitals and health centers,” said Fred DeGrandis, CEO and president of Cleveland Clinic Regional Hospitals. Here’s the release.

Parexel is expanding in Connecticut, with a lease of new office space in Stamford.

{embed=“includes/banner_ads” loc=“Third”}

Praxis, a company specializing in patient recruitment, is providing services to an unidentified biotech company for three national trials in women’s health. Praxis created one umbrella recruitment program uniquely targeted to the patient population required. Said David Fox, president and CEO of Praxis: “This program cultivates a new relationship with an exciting biotechnology company and enhances our expertise in the area of women’s health—an area we have significant experience in. These studies will also benefit from PraxisDirect 2.0, our recently-enhanced study management technology that offers our sponsor the unique convenience of logging in to one place to access enrollment metrics from all three study protocols in the program at a glance.” Here’s the release.

Frost & Sullivan is planning a series of “voice of the customer” reports on outsourcing trends, perceptions, selection criteria and other important dynamics to contract research organizations (CROs). The firm is looking for customers/supporters. Six core therapeutic areas will be the targeted: oncology, cardiovascular, metabolic, central nervous system, infectious disease, allergy & respiratory. The Frost & Sullivan studies will include detailed interviews with more than 150 executives within the pharmaceutical and biotechnology industry who are involved in outsourcing to CROs. “Understanding how outsourcers make decisions and evaluate providers is vital to service companies,” notes Frost & Sullivan industry manager Daniel Ruppar. “Analyzing feedback on these dynamics provides CROs a sound basis for formulating an effective strategy to compete in the marketplace.” The studies will survey CRO customers to better understand their preferences, in addition to current and future outsourcing patterns. Here’s the release.

Have a news release? Send it to .